Goldman Sachs Resumed BioMed Realty (BMR) at Neutral

Goldman Sachs resumed coverage on BioMed Realty (NYSE: BMR) with a Neutral rating at a price target of $21. Analyst Matthew Rand said he sees better value elsewhere.

"BMR's earnings growth could be below the sector average in the coming years given ongoing challenges in the lab sector, additional tenant vacancies over the next few years, and higher G&A levels related to the Wexford acquisition," said Rand. "We continue to think that Digital Realty Trust (NYSE: DLR) offers better value as well as better growth within the more capital-intensive, slow-growth property sectors."

For an analyst ratings summary and ratings history on BioMed Realty click here. For more ratings news on BioMed Realty click here.

Shares of BioMed Realty closed at $20.50 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat